Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)
| 1.62 Delayed Data As of May 25 |  -0.01 / -0.62%Today’s Change | 1.56 Today|||52-Week Range 6.33 | -58.88% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $265.5M |
Company Description
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Contact Information
Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Boulevard The Woodlands Texas 77381-1160 |
Employees
Shareholders
| Mutual fund holders | 9.86% |
| Other institutional | 69.09% |
| Individual stakeholders | 51.95% |
Top Executives
| Lonnel Coats | Chief Executive Officer & Director |
| Jeffrey L. Wade | President & Chief Financial Officer |
| Craig B. Granowitz | Chief Medical Officer & Senior Vice President |
| Brian T. Crum | Secretary, Senior Vice President & General Counsel |
| Kiernan A. Seth | Chief Commercial Officer & Vice President |
